ID   G6PC3_HUMAN             Reviewed;         346 AA.
AC   Q9BUM1; Q8WU15;
DT   20-MAY-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2004, sequence version 2.
DT   15-MAR-2017, entry version 134.
DE   RecName: Full=Glucose-6-phosphatase 3;
DE            Short=G-6-Pase 3;
DE            Short=G6Pase 3;
DE            EC=3.1.3.9;
DE   AltName: Full=Glucose-6-phosphatase beta;
DE            Short=G6Pase-beta;
DE   AltName: Full=Ubiquitous glucose-6-phosphatase catalytic subunit-related protein;
GN   Name=G6PC3; Synonyms=UGRP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=12370122; DOI=10.1677/jme.0.0290205;
RA   Martin C.C., Oeser J.K., Svitek C.A., Hunter S.I., Hutton J.C.,
RA   O'Brien R.M.;
RT   "Identification and characterization of a human cDNA and gene encoding
RT   a ubiquitously expressed glucose-6-phosphatase catalytic subunit-
RT   related protein.";
RL   J. Mol. Endocrinol. 29:205-222(2002).
RN   [4]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=12965222; DOI=10.1016/S0014-5793(03)00903-7;
RA   Guionie O., Clottes E., Stafford K., Burchell A.;
RT   "Identification and characterisation of a new human glucose-6-
RT   phosphatase isoform.";
RL   FEBS Lett. 551:159-164(2003).
RN   [5]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF ARG-79; HIS-114 AND HIS-167.
RX   PubMed=13129915; DOI=10.1074/jbc.M309472200;
RA   Shieh J.-J., Pan C.-J., Mansfield B.C., Chou J.Y.;
RT   "A glucose-6-phosphate hydrolase, widely expressed outside the liver,
RT   can explain age-dependent resolution of hypoglycemia in glycogen
RT   storage disease type Ia.";
RL   J. Biol. Chem. 278:47098-47103(2003).
RN   [6]
RP   TOPOLOGY, AND ACTIVE SITE.
RX   PubMed=14718531; DOI=10.1074/jbc.M313271200;
RA   Ghosh A., Shieh J.-J., Pan C.-J., Chou J.Y.;
RT   "Histidine 167 is the phosphate acceptor in glucose-6-phosphatase-beta
RT   forming a phosphohistidine enzyme intermediate during catalysis.";
RL   J. Biol. Chem. 279:12479-12483(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=14765991; DOI=10.1677/jme.0.0320033;
RA   Boustead J.N., Martin C.C., Oeser J.K., Svitek C.A., Hunter S.I.,
RA   Hutton J.C., O'Brien R.M.;
RT   "Identification and characterization of a cDNA and the gene encoding
RT   the mouse ubiquitously expressed glucose-6-phosphatase catalytic
RT   subunit-related protein.";
RL   J. Mol. Endocrinol. 32:33-53(2004).
RN   [8]
RP   VARIANTS SCN4 PRO-185; HIS-253 AND ARG-262, AND CHARACTERIZATION OF
RP   VARIANT SCN4 HIS-253.
RX   PubMed=19118303; DOI=10.1056/NEJMoa0805051;
RA   Boztug K., Appaswamy G., Ashikov A., Schaeffer A.A., Salzer U.,
RA   Diestelhorst J., Germeshausen M., Brandes G., Lee-Gossler J.,
RA   Noyan F., Gatzke A.-K., Minkov M., Greil J., Kratz C., Petropoulou T.,
RA   Pellier I., Bellanne-Chantelot C., Rezaei N., Moenkemoeller K.,
RA   Irani-Hakimeh N., Bakker H., Gerardy-Schahn R., Zeidler C.,
RA   Grimbacher B., Welte K., Klein C.;
RT   "A syndrome with congenital neutropenia and mutations in G6PC3.";
RL   N. Engl. J. Med. 360:32-43(2009).
RN   [9]
RP   VARIANT DURSS VAL-116.
RX   PubMed=20799326; DOI=10.1002/ajmg.a.33615;
RA   Banka S., Newman W.G., Ozgul R.K., Dursun A.;
RT   "Mutations in the G6PC3 gene cause Dursun syndrome.";
RL   Am. J. Med. Genet. A 152:2609-2611(2010).
RN   [10]
RP   VARIANT SCN4 ARG-260, AND CHARACTERIZATION OF VARIANT SCN4 ARG-260.
RX   PubMed=20616219; DOI=10.1182/blood-2010-01-265942;
RA   McDermott D.H., De Ravin S.S., Jun H.S., Liu Q., Priel D.A., Noel P.,
RA   Takemoto C.M., Ojode T., Paul S.M., Dunsmore K.P., Hilligoss D.,
RA   Marquesen M., Ulrick J., Kuhns D.B., Chou J.Y., Malech H.L.,
RA   Murphy P.M.;
RT   "Severe congenital neutropenia resulting from G6PC3 deficiency with
RT   increased neutrophil CXCR4 expression and myelokathexis.";
RL   Blood 116:2793-2802(2010).
RN   [11]
RP   VARIANTS SCN4 LYS-116; GLN-189 AND ARG-260.
RX   PubMed=20220065; DOI=10.3324/haematol.2009.017665;
RA   Germeshausen M., Zeidler C., Stuhrmann M., Lanciotti M., Ballmaier M.,
RA   Welte K.;
RT   "Digenic mutations in severe congenital neutropenia.";
RL   Haematologica 95:1207-1210(2010).
RN   [12]
RP   VARIANTS SCN4 SER-44; 64-THR--ILE-70 DEL AND ARG-208, AND
RP   CHARACTERIZATION OF VARIANTS SCN4 SER-44 AND 64-THR--ILE-70 DEL.
RX   PubMed=22469094; DOI=10.1111/j.1365-2141.2012.09110.x;
RA   Smith B.N., Evans C., Ali A., Ancliff P.J., Hayee B., Segal A.W.,
RA   Hall G., Kaya Z., Shakoori A.R., Linch D.C., Gale R.E.;
RT   "Phenotypic heterogeneity and evidence of a founder effect associated
RT   with G6PC3 mutations in patients with severe congenital neutropenia.";
RL   Br. J. Haematol. 158:146-149(2012).
RN   [13]
RP   VARIANTS SCN4 LEU-44; LYS-116; ILE-139; GLN-161; HIS-253; ARG-260 AND
RP   ASP-260.
RX   PubMed=22050868; DOI=10.1016/j.jpeds.2011.09.019;
RA   Boztug K., Rosenberg P.S., Dorda M., Banka S., Moulton T., Curtin J.,
RA   Rezaei N., Corns J., Innis J.W., Avci Z., Tran H.C., Pellier I.,
RA   Pierani P., Fruge R., Parvaneh N., Mamishi S., Mody R., Darbyshire P.,
RA   Motwani J., Murray J., Buchanan G.R., Newman W.G., Alter B.P.,
RA   Boxer L.A., Donadieu J., Welte K., Klein C.;
RT   "Extended spectrum of human glucose-6-phosphatase catalytic subunit 3
RT   deficiency: novel genotypes and phenotypic variability in severe
RT   congenital neutropenia.";
RL   J. Pediatr. 160:679-683(2012).
RN   [14]
RP   VARIANT SCN4 ARG-325.
RX   PubMed=24105461; DOI=10.1007/s10875-013-9945-7;
RA   Alangari A.A., Alsultan A., Osman M.E., Anazi S., Alkuraya F.S.;
RT   "A novel homozygous mutation in G6PC3 presenting as cyclic neutropenia
RT   and severe congenital neutropenia in the same family.";
RL   J. Clin. Immunol. 33:1403-1406(2013).
RN   [15]
RP   VARIANTS SCN4 SER-44; THR-116 AND CYS-253.
RX   PubMed=23298686; DOI=10.1016/j.ymgme.2012.12.001;
RA   Banka S., Wynn R., Byers H., Arkwright P.D., Newman W.G.;
RT   "G6PC3 mutations cause non-syndromic severe congenital neutropenia.";
RL   Mol. Genet. Metab. 108:138-141(2013).
RN   [16]
RP   VARIANT SCN4 PRO-154.
RX   PubMed=23018568; DOI=10.1097/MPH.0b013e3182679000;
RA   Aytekin C., Germeshausen M., Tuygun N., Dogu F., Ikinciogullari A.;
RT   "A novel G6PC3 gene mutation in a patient with severe congenital
RT   neutropenia.";
RL   J. Pediatr. Hematol. Oncol. 35:E81-E83(2013).
RN   [17]
RP   VARIANT SCN4 ARG-59.
RX   PubMed=24750412; DOI=10.1111/ejh.12349;
RA   Arikoglu T., Kuyucu N., Germeshausen M., Kuyucu S.;
RT   "A novel G6PC3 gene mutation in severe congenital neutropenia:
RT   pancytopenia and variable bone marrow phenotype can also be part of
RT   this syndrome.";
RL   Eur. J. Haematol. 94:79-82(2015).
RN   [18]
RP   CHARACTERIZATION OF VARIANTS SCN4 LEU-44; SER-44; ILE-116; LYS-116;
RP   THR-116; VAL-116; ARG-118; ILE-139; PRO-154; GLN-161; PRO-185;
RP   GLN-189; ARG-208; HIS-253; ARG-260 AND ASP-260.
RX   PubMed=25492228; DOI=10.1016/j.ymgme.2014.11.012;
RA   Lin S.R., Pan C.J., Mansfield B.C., Chou J.Y.;
RT   "Functional analysis of mutations in a severe congenital neutropenia
RT   syndrome caused by glucose-6-phosphatase-beta deficiency.";
RL   Mol. Genet. Metab. 114:41-45(2015).
CC   -!- FUNCTION: Hydrolyzes glucose-6-phosphate to glucose in the
CC       endoplasmic reticulum. May form with the glucose-6-phosphate
CC       transporter (SLC37A4/G6PT) a ubiquitously expressed complex
CC       responsible for glucose production through glycogenolysis and
CC       gluconeogenesis. Probably required for normal neutrophil function.
CC       {ECO:0000269|PubMed:12370122, ECO:0000269|PubMed:12965222,
CC       ECO:0000269|PubMed:13129915}.
CC   -!- CATALYTIC ACTIVITY: D-glucose 6-phosphate + H(2)O = D-glucose +
CC       phosphate. {ECO:0000269|PubMed:12965222}.
CC   -!- ENZYME REGULATION: Inhibited by vanadate.
CC       {ECO:0000269|PubMed:13129915}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.0 mM for glucose-6-phosphate (at pH 5.5)
CC         {ECO:0000269|PubMed:12965222, ECO:0000269|PubMed:13129915};
CC         KM=2.0 mM for glucose-6-phosphate (at pH 6.5)
CC         {ECO:0000269|PubMed:12965222, ECO:0000269|PubMed:13129915};
CC         Note=8 times less active compared to G6PC under the same
CC         experimental conditions.;
CC   -!- PATHWAY: Carbohydrate biosynthesis; gluconeogenesis.
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:13129915}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:13129915}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed. Highly expressed in
CC       skeletal muscle, at intermediate levels in heart, brain, placenta,
CC       kidney, colon, thymus, spleen and pancreas. Also detected in
CC       testis, prostate, ovary, liver, lung, small intestine and
CC       peripheral blood lymphocytes. {ECO:0000269|PubMed:12370122,
CC       ECO:0000269|PubMed:12965222, ECO:0000269|PubMed:14765991}.
CC   -!- DISEASE: Neutropenia, severe congenital 4, autosomal recessive
CC       (SCN4) [MIM:612541]: A disorder of hematopoiesis characterized by
CC       maturation arrest of granulopoiesis at the level of promyelocytes
CC       with peripheral blood absolute neutrophil counts below 0.5 x
CC       10(9)/l and early onset of severe bacterial infections.
CC       {ECO:0000269|PubMed:19118303, ECO:0000269|PubMed:20220065,
CC       ECO:0000269|PubMed:20616219, ECO:0000269|PubMed:22050868,
CC       ECO:0000269|PubMed:22469094, ECO:0000269|PubMed:23018568,
CC       ECO:0000269|PubMed:23298686, ECO:0000269|PubMed:24105461,
CC       ECO:0000269|PubMed:24750412, ECO:0000269|PubMed:25492228}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Dursun syndrome (DURSS) [MIM:612541]: A disease
CC       characterized by pulmonary arterial hypertension, cardiac
CC       abnormalities including secundum-type atrial septal defect,
CC       intermittent neutropenia, lymphopenia, monocytosis and anemia.
CC       {ECO:0000269|PubMed:20799326}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the glucose-6-phosphatase family.
CC       {ECO:0000305}.
CC   -!- CAUTION: According to PubMed:12370122, it has no hydrolytic
CC       activity. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH471178; EAW51638.1; -; Genomic_DNA.
DR   EMBL; BC002494; AAH02494.2; -; mRNA.
DR   EMBL; BC021574; AAH21574.1; -; mRNA.
DR   CCDS; CCDS11476.1; -.
DR   RefSeq; NP_612396.1; NM_138387.3.
DR   UniGene; Hs.294005; -.
DR   ProteinModelPortal; Q9BUM1; -.
DR   STRING; 9606.ENSP00000269097; -.
DR   DEPOD; Q9BUM1; -.
DR   iPTMnet; Q9BUM1; -.
DR   PhosphoSitePlus; Q9BUM1; -.
DR   SwissPalm; Q9BUM1; -.
DR   BioMuta; G6PC3; -.
DR   DMDM; 74733234; -.
DR   EPD; Q9BUM1; -.
DR   MaxQB; Q9BUM1; -.
DR   PaxDb; Q9BUM1; -.
DR   PeptideAtlas; Q9BUM1; -.
DR   PRIDE; Q9BUM1; -.
DR   Ensembl; ENST00000269097; ENSP00000269097; ENSG00000141349.
DR   GeneID; 92579; -.
DR   KEGG; hsa:92579; -.
DR   UCSC; uc002iex.4; human.
DR   CTD; 92579; -.
DR   DisGeNET; 92579; -.
DR   GeneCards; G6PC3; -.
DR   H-InvDB; HIX0013874; -.
DR   HGNC; HGNC:24861; G6PC3.
DR   HPA; HPA067052; -.
DR   MalaCards; G6PC3; -.
DR   MIM; 611045; gene.
DR   MIM; 612541; phenotype.
DR   neXtProt; NX_Q9BUM1; -.
DR   OpenTargets; ENSG00000141349; -.
DR   Orphanet; 331176; Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency.
DR   PharmGKB; PA134968446; -.
DR   eggNOG; ENOG410IDXG; Eukaryota.
DR   eggNOG; ENOG4110AJ7; LUCA.
DR   GeneTree; ENSGT00510000046465; -.
DR   HOGENOM; HOG000264239; -.
DR   HOVERGEN; HBG003560; -.
DR   InParanoid; Q9BUM1; -.
DR   KO; K01084; -.
DR   OMA; HMFSAQE; -.
DR   OrthoDB; EOG091G0AXF; -.
DR   PhylomeDB; Q9BUM1; -.
DR   TreeFam; TF324388; -.
DR   BioCyc; MetaCyc:HS13873-MONOMER; -.
DR   BRENDA; 3.1.3.9; 2681.
DR   Reactome; R-HSA-70153; Glucose transport.
DR   SABIO-RK; Q9BUM1; -.
DR   UniPathway; UPA00138; -.
DR   ChiTaRS; G6PC3; human.
DR   GeneWiki; G6PC3; -.
DR   GenomeRNAi; 92579; -.
DR   PRO; PR:Q9BUM1; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141349; -.
DR   CleanEx; HS_G6PC3; -.
DR   ExpressionAtlas; Q9BUM1; baseline and differential.
DR   Genevisible; Q9BUM1; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0030176; C:integral component of endoplasmic reticulum membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0004346; F:glucose-6-phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0006094; P:gluconeogenesis; IBA:GO_Central.
DR   GO; GO:0051156; P:glucose 6-phosphate metabolic process; IBA:GO_Central.
DR   GO; GO:0015758; P:glucose transport; TAS:Reactome.
DR   GO; GO:0015760; P:glucose-6-phosphate transport; IEA:Ensembl.
DR   Gene3D; 1.20.144.10; -; 1.
DR   InterPro; IPR016275; Glucose-6-phosphatase.
DR   InterPro; IPR000326; P_Acid_Pase_2/haloperoxidase.
DR   Pfam; PF01569; PAP2; 1.
DR   PIRSF; PIRSF000905; Glucose-6-phosphatase; 1.
DR   SMART; SM00014; acidPPc; 1.
DR   SUPFAM; SSF48317; SSF48317; 1.
PE   1: Evidence at protein level;
KW   Complete proteome; Disease mutation; Endoplasmic reticulum;
KW   Gluconeogenesis; Hydrolase; Membrane; Polymorphism;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN         1    346       Glucose-6-phosphatase 3.
FT                                /FTId=PRO_0000334512.
FT   TOPO_DOM      1     24       Lumenal. {ECO:0000255}.
FT   TRANSMEM     25     45       Helical. {ECO:0000255}.
FT   TOPO_DOM     46     54       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     55     75       Helical. {ECO:0000255}.
FT   TOPO_DOM     76    114       Lumenal. {ECO:0000255}.
FT   TRANSMEM    115    135       Helical. {ECO:0000255}.
FT   TOPO_DOM    136    146       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    147    164       Helical. {ECO:0000255}.
FT   TOPO_DOM    165    169       Lumenal. {ECO:0000255}.
FT   TRANSMEM    170    186       Helical. {ECO:0000255}.
FT   TOPO_DOM    187    197       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    198    218       Helical. {ECO:0000255}.
FT   TOPO_DOM    219    254       Lumenal. {ECO:0000255}.
FT   TRANSMEM    255    273       Helical. {ECO:0000255}.
FT   TOPO_DOM    274    283       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    284    304       Helical. {ECO:0000255}.
FT   TOPO_DOM    305    307       Lumenal. {ECO:0000255}.
FT   TRANSMEM    308    328       Helical. {ECO:0000255}.
FT   TOPO_DOM    329    346       Cytoplasmic. {ECO:0000255}.
FT   ACT_SITE    114    114       Proton donor. {ECO:0000255}.
FT   ACT_SITE    167    167       Nucleophile.
FT                                {ECO:0000269|PubMed:14718531}.
FT   BINDING      79     79       Substrate. {ECO:0000255}.
FT   BINDING     161    161       Substrate. {ECO:0000255}.
FT   VARIANT      44     44       P -> L (in SCN4; complete loss of
FT                                activity; dbSNP:rs762019955).
FT                                {ECO:0000269|PubMed:22050868,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_073174.
FT   VARIANT      44     44       P -> S (in SCN4; complete loss of
FT                                activity; purified neutrophils from
FT                                patients have higher levels of
FT                                spontaneous and staurosporine-induced
FT                                apoptosis than controls;
FT                                dbSNP:rs775224457).
FT                                {ECO:0000269|PubMed:22469094,
FT                                ECO:0000269|PubMed:23298686,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_072753.
FT   VARIANT      59     59       W -> R (in SCN4; dbSNP:rs752966267).
FT                                {ECO:0000269|PubMed:24750412}.
FT                                /FTId=VAR_072754.
FT   VARIANT      64     70       Missing (in SCN4; purified neutrophils
FT                                from patients have higher levels of
FT                                spontaneous and staurosporine-induced
FT                                apoptosis than controls).
FT                                {ECO:0000269|PubMed:22469094}.
FT                                /FTId=VAR_072755.
FT   VARIANT     116    116       M -> I (in SCN4; complete loss of
FT                                activity). {ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_073175.
FT   VARIANT     116    116       M -> K (in SCN4; the patient also carries
FT                                mutation Thr-166 in ELANE; complete loss
FT                                of activity).
FT                                {ECO:0000269|PubMed:20220065,
FT                                ECO:0000269|PubMed:22050868,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_064508.
FT   VARIANT     116    116       M -> T (in SCN4; complete loss of
FT                                activity). {ECO:0000269|PubMed:23298686,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_072756.
FT   VARIANT     116    116       M -> V (in DURSS and SCN4; complete loss
FT                                of activity; dbSNP:rs267606834).
FT                                {ECO:0000269|PubMed:20799326,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_064509.
FT   VARIANT     118    118       T -> R (in SCN4; complete loss of
FT                                activity; dbSNP:rs766706036).
FT                                {ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_073176.
FT   VARIANT     139    139       S -> I (in SCN4; partial loss of
FT                                activity). {ECO:0000269|PubMed:22050868,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_072757.
FT   VARIANT     154    154       L -> P (in SCN4; complete loss of
FT                                activity). {ECO:0000269|PubMed:23018568,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_072758.
FT   VARIANT     161    161       R -> Q (in SCN4; complete loss of
FT                                activity). {ECO:0000269|PubMed:22050868,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_073177.
FT   VARIANT     185    185       L -> P (in SCN4; complete loss of
FT                                activity; dbSNP:rs118203969).
FT                                {ECO:0000269|PubMed:19118303,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_055156.
FT   VARIANT     189    189       R -> Q (in SCN4; partial loss of
FT                                activity; dbSNP:rs140294222).
FT                                {ECO:0000269|PubMed:20220065,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_064510.
FT   VARIANT     208    208       L -> R (in SCN4; complete loss of
FT                                activity). {ECO:0000269|PubMed:22469094,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_072759.
FT   VARIANT     216    216       T -> I (in dbSNP:rs34406052).
FT                                /FTId=VAR_043378.
FT   VARIANT     253    253       R -> C (in SCN4; dbSNP:rs765927570).
FT                                {ECO:0000269|PubMed:23298686}.
FT                                /FTId=VAR_073178.
FT   VARIANT     253    253       R -> H (in SCN4; complete loss of
FT                                activity; peripheral-blood patient
FT                                neutrophils have an increased rate of
FT                                spontaneous apoptosis; transmission
FT                                electron microscopy of patient bone
FT                                marrow cells shows an enlarged rough
FT                                endoplasmic reticulum in myeloid
FT                                progenitor cells consistent with
FT                                increased ER stress; dbSNP:rs118203968).
FT                                {ECO:0000269|PubMed:19118303,
FT                                ECO:0000269|PubMed:22050868,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_055157.
FT   VARIANT     260    260       G -> D (in SCN4; complete loss of
FT                                activity). {ECO:0000269|PubMed:22050868,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_072760.
FT   VARIANT     260    260       G -> R (in SCN4; complete loss of
FT                                activity; dbSNP:rs200478425).
FT                                {ECO:0000269|PubMed:20220065,
FT                                ECO:0000269|PubMed:20616219,
FT                                ECO:0000269|PubMed:22050868,
FT                                ECO:0000269|PubMed:25492228}.
FT                                /FTId=VAR_064511.
FT   VARIANT     262    262       G -> R (in SCN4; dbSNP:rs118203971).
FT                                {ECO:0000269|PubMed:19118303}.
FT                                /FTId=VAR_055158.
FT   VARIANT     325    325       L -> R (in SCN4).
FT                                {ECO:0000269|PubMed:24105461}.
FT                                /FTId=VAR_072761.
FT   MUTAGEN      79     79       R->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:13129915}.
FT   MUTAGEN     114    114       H->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:13129915}.
FT   MUTAGEN     167    167       H->A: Loss of catalytic activity.
FT                                {ECO:0000269|PubMed:13129915}.
SQ   SEQUENCE   346 AA;  38735 MW;  55C1F322E59C8439 CRC64;
     MESTLGAGIV IAEALQNQLA WLENVWLWIT FLGDPKILFL FYFPAAYYAS RRVGIAVLWI
     SLITEWLNLI FKWFLFGDRP FWWVHESGYY SQAPAQVHQF PSSCETGPGS PSGHCMITGA
     ALWPIMTALS SQVATRARSR WVRVMPSLAY CTFLLAVGLS RIFILAHFPH QVLAGLITGA
     VLGWLMTPRV PMERELSFYG LTALALMLGT SLIYWTLFTL GLDLSWSISL AFKWCERPEW
     IHVDSRPFAS LSRDSGAALG LGIALHSPCY AQVRRAQLGN GQKIACLVLA MGLLGPLDWL
     GHPPQISLFY IFNFLKYTLW PCLVLALVPW AVHMFSAQEA PPIHSS
//
